What is the recommended initial dose of antivenom (CroFab, Crotalidae polyvalent immune fab) for a patient presenting with a hemorrhagic snake bite?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Initial Dose of Antivenom for Hemorrhagic Snake Bite

The recommended initial dose of CroFab (Crotalidae polyvalent immune Fab) is 4 to 6 vials administered intravenously, though the starting dose may range from a minimum of 4 vials to a maximum of 12 vials based on severity of envenomation. 1

Initial Dosing Protocol

The FDA-approved dosing for CroFab starts with 4 to 6 vials as the standard initial dose, with flexibility to administer up to 12 vials for severe envenomation. 1 This represents the official prescribing information and should guide initial management. However, expert consensus guidelines suggest that 10 vials offers practical advantages as a single initial dose without increasing adverse reaction risk. 2

Dose Administration Steps:

  • Reconstitute each vial with 18 mL of 0.9% sodium chloride, then dilute all reconstituted vials to a total volume of 250 mL. 1
  • Infuse intravenously over 60 minutes, starting slowly at 25-50 mL/hour for the first 10 minutes while monitoring for allergic reactions. 1
  • If no reaction occurs, increase to full rate of 250 mL/hour until completion. 1

Assessing Initial Control

Observe the patient for up to 1 hour following completion of the first dose to determine if initial control has been achieved. 1 Initial control is defined as:

  • Arrest of local injury progression (leading edge stops advancing) 1
  • Resolution of systemic symptoms 1
  • Normalization or trending toward normal of coagulation parameters 1

Repeat Dosing if Initial Control Not Achieved

If initial control is not achieved with the first dose, administer an additional 4 to 6 vials repeatedly until initial control is established. 1 This may require multiple rounds of dosing depending on severity of envenomation and individual patient response.

Maintenance Dosing After Initial Control

Once initial control is achieved, administer 2 vials every 6 hours for up to 18 hours (3 doses total). 1 This maintenance regimen is critical, as recurrent and delayed-onset coagulopathy commonly occurs in patients who do not receive recommended maintenance dosing. 3

Hospital Preparedness

Hospitals in areas endemic for crotaline snakes should stock at least 12 vials of antivenom, though this may be insufficient if multiple simultaneous bites require treatment. 4, 2 Facilities should perform a hazard vulnerability assessment to determine appropriate stocking levels based on geographic location and local snake species. 2, 5

Critical Pitfalls to Avoid

  • Do not delay antivenom administration—CroFab is most effective when given within 6 hours of snakebite. 1
  • Do not assume adequate treatment after initial control—failure to provide maintenance dosing leads to recurrent coagulopathy. 3
  • Have epinephrine readily available (0.3-0.5 mg IM for adults, 0.01 mg/kg up to 0.3 mg for children) for potential anaphylactic reactions. 2
  • Infusion reactions such as fever, low back pain, wheezing, and nausea may be controlled by decreasing the infusion rate. 1

Evidence Quality Considerations

The FDA label 1 provides the definitive dosing range of 4-12 vials based on severity, while expert consensus 2 suggests 10 vials as a practical starting point. Research evidence supports that the median dose to achieve initial control is 6 vials (range 4-18 vials). 3 Importantly, initial control was achieved in 50% of severe envenomation cases in published literature, with higher success rates (100%) in cohort studies versus case reports (29%). 3

References

Guideline

Anti-Snake Venom Administration Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Snakebite Management Guidelines

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.